PT3790879T - Compostos de triazolopirimidina e a sua utilização no tratamento de cancro - Google Patents

Compostos de triazolopirimidina e a sua utilização no tratamento de cancro

Info

Publication number
PT3790879T
PT3790879T PT197234040T PT19723404T PT3790879T PT 3790879 T PT3790879 T PT 3790879T PT 197234040 T PT197234040 T PT 197234040T PT 19723404 T PT19723404 T PT 19723404T PT 3790879 T PT3790879 T PT 3790879T
Authority
PT
Portugal
Prior art keywords
treating cancer
triazolopyrimidine compounds
triazolopyrimidine
compounds
cancer
Prior art date
Application number
PT197234040T
Other languages
English (en)
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of PT3790879T publication Critical patent/PT3790879T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT197234040T 2018-05-11 2019-05-10 Compostos de triazolopirimidina e a sua utilização no tratamento de cancro PT3790879T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862670075P 2018-05-11 2018-05-11

Publications (1)

Publication Number Publication Date
PT3790879T true PT3790879T (pt) 2022-08-26

Family

ID=66484070

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197234040T PT3790879T (pt) 2018-05-11 2019-05-10 Compostos de triazolopirimidina e a sua utilização no tratamento de cancro

Country Status (16)

Country Link
US (3) US11084827B2 (pt)
EP (2) EP4134368A1 (pt)
JP (1) JP7418353B2 (pt)
KR (1) KR102863374B1 (pt)
CN (3) CN112469721B (pt)
AR (1) AR115384A1 (pt)
AU (1) AU2019264826B2 (pt)
BR (1) BR112020023068A2 (pt)
CA (1) CA3099579A1 (pt)
DK (1) DK3790879T3 (pt)
ES (1) ES2927244T3 (pt)
MX (1) MX2020012058A (pt)
PT (1) PT3790879T (pt)
TW (1) TWI823932B (pt)
UY (1) UY38228A (pt)
WO (1) WO2019215316A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
JP2023515618A (ja) * 2020-02-28 2023-04-13 リミックス セラピューティクス インコーポレイテッド 核酸スプライシングを調節するためのピリダジン誘導体
EP4153652A1 (en) * 2020-05-21 2023-03-29 Teon Therapeutics, Inc. Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
CN116801906A (zh) 2020-11-02 2023-09-22 阿雷斯贸易股份有限公司 癌症的联合治疗
US20240270749A1 (en) 2021-05-21 2024-08-15 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use
WO2025201236A1 (zh) * 2024-03-25 2025-10-02 北京福元医药股份有限公司 Mct4抑制剂及其药物组合物和用途
CN121735952A (zh) * 2026-02-26 2026-03-27 山东齐都药业有限公司 维立西呱的制备方法及其中间产物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) * 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
DE102005034905A1 (de) 2005-07-26 2007-02-01 Federal-Mogul Nürnberg GmbH Verfahren zur Herstellung eines Kolbens für einen Verbrennungsmotor sowie Kolben für einen Verbrennungsmotor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2016118823A1 (en) 2015-01-22 2016-07-28 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
JP6725519B2 (ja) * 2015-01-22 2020-07-22 ザ スクリプス リサーチ インスティテュート 複素環式のモノカルボン酸トランスポータ阻害薬
AU2016277126A1 (en) * 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
US20190135747A1 (en) * 2016-05-12 2019-05-09 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
AU2019264826A1 (en) 2020-11-26
AU2019264826B2 (en) 2024-05-23
US11851432B2 (en) 2023-12-26
JP7418353B2 (ja) 2024-01-19
UY38228A (es) 2019-10-31
US11084827B2 (en) 2021-08-10
EP4134368A1 (en) 2023-02-15
AR115384A1 (es) 2021-01-13
CN115028636A (zh) 2022-09-09
CN112469721B (zh) 2022-06-07
TW202015674A (zh) 2020-05-01
KR102863374B1 (ko) 2025-09-22
JP2021523177A (ja) 2021-09-02
US12503473B2 (en) 2025-12-23
BR112020023068A2 (pt) 2021-02-09
EP3790879A1 (en) 2021-03-17
CN115028637A (zh) 2022-09-09
KR20210013078A (ko) 2021-02-03
TWI823932B (zh) 2023-12-01
CN112469721A (zh) 2021-03-09
CN115028637B (zh) 2024-03-22
US20240217980A1 (en) 2024-07-04
EP3790879B1 (en) 2022-06-29
DK3790879T3 (da) 2022-08-29
US20210340150A1 (en) 2021-11-04
US20210087196A1 (en) 2021-03-25
WO2019215316A1 (en) 2019-11-14
ES2927244T3 (es) 2022-11-03
MX2020012058A (es) 2021-02-26
CA3099579A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
ZA202100195B (en) Purinone compounds and their use in treating cancer
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
SG11202104356VA (en) Bt1718 for use in treating cancer
GB201719076D0 (en) Particles for the treatment of cancer in combination with radiotherapy
PL3860990T3 (pl) Inhibitory oddziaływania yap/taz-tead i ich zastosowanie w leczeniu nowotworów
EP3250609A4 (en) Il13ra alpha 2 binding agents and use thereof in cancer treatment
SG11202104571RA (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
IL281495A (en) Quinuclidine-3-one derivatives and their use in cancer treatment
IL286334B1 (en) Modified microRNAs and their use in cancer treatment
IL284053A (en) New compounds and their use in therapy
ZA201804361B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL259510A (en) 1, 3, 4-thiadiazole compounds and their use for cancer treatment
IL258644A (en) 4,3,1-thiadiazole compounds and their use for cancer treatment
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
SG11202105276TA (en) Oligo-benzamide analogs and their use in cancer treatment
IL269121A (en) Usl-311 for use in the treatment of cancer
IL277038A (en) Bexarotane derivatives and their use for cancer treatment
GB201514018D0 (en) Novel tricyclic compounds and their use in the treatment of cancer
IL273054B2 (en) Abx196 for use in the treatment of bladder cancer
PL3752513T3 (pl) Dwujądrowe palladocykle i ich zastosowanie w leczeniu nowotworów złośliwych
HK40064163A (en) Oligo-benzamide analogs and their use in cancer treatment
HK40060258A (zh) 用於治疗癌症的bt1718
IL277112A (en) Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer
ZA201900976B (en) Binuclear palladacycles and their use in the treatment of cancer